X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse IPCA Labs with ADCOCK INGRAM HOLDINGS LTD. - S. Africa - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA LABS vs ADCOCK INGRAM (S. Africa) - Comparison Results

IPCA LABS    Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

ADCOCK INGRAM (S. Africa)
   Change

Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 IPCA LABS   ADCOCK INGRAM
EQUITY SHARE DATA
    IPCA LABS
Mar-17
ADCOCK INGRAM
Jun-14
IPCA LABS/
ADCOCK INGRAM
5-Yr Chart
Click to enlarge
High Rs643403-   
Low Rs503291-   
Sales per share (Unadj.) Rs254.4119.9-  
Earnings per share (Unadj.) Rs16.1-30.2-  
Cash flow per share (Unadj.) Rs29.8-25.0-  
Dividends per share (Unadj.) Rs1.000-  
Dividend yield (eoy) %0.20-  
Book value per share (Unadj.) Rs194.694.1-  
Shares outstanding (eoy) m126.20168.78-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.32.9 77.8%   
Avg P/E ratio x35.7-11.5 -310.5%  
P/CF ratio (eoy) x19.2-13.9 -138.9%  
Price / Book Value ratio x2.93.7 79.9%  
Dividend payout %6.20-   
Avg Mkt Cap Rs m72,30058,557 123.5%   
No. of employees `00013.34.3 309.9%   
Total wages/salary Rs m6,9603,675 189.4%   
Avg. sales/employee Rs Th2,413.54,714.3 51.2%   
Avg. wages/employee Rs Th523.2856.1 61.1%   
Avg. net profit/employee Rs Th152.4-1,187.9 -12.8%   
INCOME DATA
Net Sales Rs m32,10620,238 158.6%  
Other income Rs m226142 159.3%   
Total revenues Rs m32,33220,380 158.6%   
Gross profit Rs m4,448-3,507 -126.8%  
Depreciation Rs m1,730873 198.0%   
Interest Rs m241548 43.9%   
Profit before tax Rs m2,703-4,787 -56.5%   
Minority Interest Rs m0-13 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m675299 225.7%   
Profit after tax Rs m2,028-5,100 -39.8%  
Gross profit margin %13.9-17.3 -79.9%  
Effective tax rate %25.0-6.2 -399.7%   
Net profit margin %6.3-25.2 -25.1%  
BALANCE SHEET DATA
Current assets Rs m17,34014,823 117.0%   
Current liabilities Rs m9,5598,340 114.6%   
Net working cap to sales %24.232.0 75.7%  
Current ratio x1.81.8 102.1%  
Inventory Days Days100111 90.4%  
Debtors Days Days57124 45.9%  
Net fixed assets Rs m20,7798,640 240.5%   
Share capital Rs m25294 268.6%   
"Free" reserves Rs m24,4990-   
Net worth Rs m24,55315,885 154.6%   
Long term debt Rs m3,5175,582 63.0%   
Total assets Rs m39,59530,008 131.9%  
Interest coverage x12.2-7.7 -158.1%   
Debt to equity ratio x0.10.4 40.8%  
Sales to assets ratio x0.80.7 120.2%   
Return on assets %5.7-15.2 -37.8%  
Return on equity %8.3-32.1 -25.7%  
Return on capital %10.5-19.8 -52.9%  
Exports to sales %48.60-   
Imports to sales %14.20-   
Net fx Rs m9,7900-   
CASH FLOW
From Operations Rs m2,7641,727 160.0%  
From Investments Rs m-1,432-530 269.9%  
From Financial Activity Rs m-1,5915,066 -31.4%  
Net Cashflow Rs m-2596,263 -4.1%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ADCOCK INGRAM (S. Africa) is South Africa Rand. All data has been converted at 5.56 Rs / ZAR

Compare IPCA LABS With: ACTAVIS (US)  MYLAN (US)  TEVA PHARMA (Israel)  

Compare IPCA LABS With: PFIZER  JUBILANT LIFE SCIENCES  ELDER PHARMA  NATCO PHARMA  STERLING BIOTECH  



Today's Market

Global Stock Markets Chart Modest Gains(RoundUp)

Global financial markets ended the holiday shortened week with modest gains. The rally put behind days of decline as concerns regarding swift interest rates hikes were put to ease.

Related Views On News

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

IPCA LABS SHARE PRICE


Feb 23, 2018 (Close)

TRACK IPCA LABS

  • Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

IPCA LABS - AJANTA PHARMA COMPARISON

COMPARE IPCA LABS WITH

MARKET STATS